Cleveland BioLabs (Cleveland BioLabs) Operating Income : $-2.69 Mil (TTM As of Mar. 2021)

View and export this data going back to 2006. Start your Free Trial

What is Cleveland BioLabs Operating Income?

Cleveland BioLabs's Operating Income for the three months ended in Mar. 2021 was $-0.55 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2021 was $-2.69 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Cleveland BioLabs's Operating Income for the three months ended in Mar. 2021 was $-0.55 Mil. Cleveland BioLabs's Revenue for the three months ended in Mar. 2021 was $0.00 Mil. Therefore, Cleveland BioLabs's Operating Margin % for the quarter that ended in Mar. 2021 was %.

Warning Sign:

Cleveland BioLabs Inc operating margin has been in 5-year decline. The average rate of decline per year is -16.6%.

Cleveland BioLabs's 5-Year average Growth Rate for Operating Margin % was -16.60% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cleveland BioLabs's annualized ROC % for the quarter that ended in Mar. 2021 was -44,080.00%. Cleveland BioLabs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was -44,080.00%.

Cleveland BioLabs Operating Income Historical Data

The historical data trend for Cleveland BioLabs's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleveland BioLabs Operating Income Chart

Cleveland BioLabs Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Operating Income

Get a 7-Day Free Trial

-6.36

-5.60

-4.80

-2.36

-2.59

Cleveland BioLabs Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Operating Income	Get a 7-Day Free Trial															-0.44	-0.59	-0.77	-0.78	-0.55

Cleveland BioLabs Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.69 Mil.

Cleveland BioLabs (NAS:CBLI) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cleveland BioLabs's annualized ROC % for the quarter that ended in Mar. 2021 is calculated as:

	ROC % (Q: Mar. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2020 )	+	Invested Capital (Q: Mar. 2021 ))	/ count )
=	-2.204 * ( 1 - 0% )	/	( (0.004	+	0.0059999999999985)	/ 2 )
=	-2.204	/	0.0049999999999992
=	-44,080.00 %

where

	Invested Capital		(Q: Dec. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.318	-	0.305	-	( 2.271	-	max(0, 0.305	-	2.314	+	2.271	))
=	0.004

	Invested Capital		(Q: Mar. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14.7	-	0.518	-	( 14.623	-	max(0, 0.518	-	14.694	+	14.623	))
=	0.0059999999999985

Note: The Operating Income data used here is four times the quarterly (Mar. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Cleveland BioLabs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2021 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2021 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2020		Q: Mar. 2021
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.204	/	( ( (0.004 + max(-0.262, 0))	+	(0.006 + max(-0.447, 0)) )	/	2 )
=	-2.204	/	( ( 0.004	+	0.006 )	/	2 )
=	-2.204	/	0.005
=	-44,080.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.012	+	0	+	0.031)	-	(0.305	+	0	+	0)
=	-0.262

	Working Capital		(Q: Mar. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.071000000000002)	-	(0.518	+	0	+	0)
=	-0.447

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2021) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Cleveland BioLabs's Operating Margin % for the quarter that ended in Mar. 2021 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2021 )	/	Revenue (Q: Mar. 2021 )
	=	-0.551	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Cleveland BioLabs Operating Income Related Terms

Thank you for viewing the detailed overview of Cleveland BioLabs's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleveland BioLabs (Cleveland BioLabs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cleveland BioLabs Inc (NAS:CBLI) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

73 High Street, Buffalo, NY, USA, 14203

Website

http://www.cbiolabs.com

Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.

Executives

Christopher Zosh	officer: Vice President of Finance	C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin	director	73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo	officer: Principal Financial Officer	73 HIGH STREET, BUFFALO NY 14203
Randy S. Saluck	director	C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin	director	73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy	director	73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev	director	73 HIGH STREET, BUFFALO NY 14203
Lea Verny	director	73 HIGH STREET, BUFFALO NY 14203
Tatiana Levina	director	10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Ivan Persiyanov	director	4 SADOVNICHESKAYA ST, MOSCOW 1Z 115035
Anna Evdokimova	director	9-96 UNIVERSITETSKIY PROSPEKT, MOSCOW 1Z 119296
Yulia Lebedina	director	5 MALYSHEVA STREET, FLAT 7, MOSCOW 1Z 109129
Konstantin Gorshkov	director	10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Saraeva	director	10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Khudyk	director	10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031